T
Tenet Healthcare Corporation
THC · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
A Surgery Center Compounder Priced Like Its Worst Segment
The market is valuing THC as a hospital company with an ASC attached, when the economic reality is increasingly the inverse — USPI is a structurally advantaged business with real physician switching costs, and the hospital segment is being intelligently harvested to fund it. The valuation gap exists because most healthcare investors pattern-match 'hospital operator' and discount the transformation as narrative rather than fact.
Flowly Score
Apr 16 Close
+186%$192.00
Fair Value
$550.00
59
Averageat $192.00
Business Strength6/10
USPI's physician co-ownership model is a genuine moat — surgeons with equity stakes don't defect easily — but the legacy hospital segment is a structural drag competing against better-capitalized nonprofits, and institutional compliance scar tissue introduces a governance discount the market is right to apply.
Financial Resilience5/10
Cash conversion quality is legitimately strong and the FCF trajectory is a real improvement, but the Altman Z sitting in the grey zone and over a decade of debt-funded expansion means the balance sheet has almost no shock absorber — a material Medicare rate cut or volume disruption hits with full leverage amplification.
Growth & Trajectory6/10
USPI's same-facility revenue growth and the inpatient-only procedure list phase-out are genuine structural tailwinds that will continue migrating high-acuity, commercially-insured volume into the better-margin segment; the hospital business is a managed decline story being harvested intelligently rather than a growth engine.
Valuation8/10at $240.59
A double-digit FCF yield and sub-seven EV/EBITDA on a business whose crown jewel is structurally gaining share reflects an extreme risk premium being applied to a debt-heavy operator — the market is pricing this like the hospital segment defines the company's future, which is exactly backwards given where capital has been flowing.
Risk4/10
The combination of heavy leverage, a compliance-scarred history, a single executive controlling legal and risk oversight simultaneously, and near-total concentration in US government reimbursement policy means this business has multiple specific vectors where a single adverse event creates non-linear downside — the debt load turns a revenue problem into a solvency conversation fast.
The investment case here is a mismatch between what the market believes it owns — a debt-laden hospital operator navigating perpetual reimbursement pressure — and what the business is actively becoming: a scaled ambulatory surgery network where physician co-ownership creates genuine economic stickiness, procedure migration tailwinds are secular and accelerating, and the capital intensity per dollar of earnings is structurally lower. The FCF yield and EV/EBITDA both scream that the market is embedding a risk premium better suited for a distressed asset than a business that just beat its own guidance by a substantial margin and is guiding to strong cash generation. The transformation is not theoretical anymore — the numbers have confirmed it. USPI's trajectory has the hallmarks of a compounding platform in early innings of its best years: the inpatient-only procedure list phase-out opens high-acuity spine and urology volume to ASC settings beginning in 2026, commercial payors are actively incentivizing the shift, and the surgeon equity model means volume that lands in a USPI center tends to stay. Conifer, underappreciated even by management, sits on a claims processing infrastructure that AI-driven automation could transform from a low-margin outsourcing business into a genuinely high-margin data platform — the optionality is real even if the timeline is uncertain. The single most specific risk is a federal Medicaid reimbursement reduction of material magnitude — not a conceptual worry but a recurring congressional budget negotiation item that has historically been narrowly avoided. If it lands, the hospital segment's already-thin margins compress immediately, debt service becomes more burdensome relative to operating cash flow, and the ASC business cannot grow fast enough to compensate in the near term. The Altman Z in the grey zone is the quantitative signal that this is not a theoretical concern — the balance sheet means there is limited room to absorb a policy shock before the capital structure becomes the story.